Biotechnology start-up Rgenta Therapeutics raised USD 52 million in a Series A funding round led by AZ-CICC Healthcare Investment Fund, with participation from existing investors and new investors. This brings the total funds raised by the company to USD 108.9 million.
The new funds will be used to advance its lead programs and pipeline of ribonucleic acid (RNA) programs, enhance target discovery, and expand its platform capabilities.
Rgenta Therapeutics is focused on discovering and developing small-molecule drugs targeting RNAs to treat oncology and neurological disorders. The company’s proprietary drug discovery platform analyzes large genomic data to identify small molecule glues that target RNAs to regulate or alter protein production and functions.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.